Back to discover

Protein / target

Keratin, type I cytoskeletal 17

Encoded byKRT17Q04695Homo sapiensSwiss-Prot
Antibody-tractable
Druggability
GO CC med conf
1
Research papers

Protein at a glance

Biological role

Structural constituent of skin epidermis

Strongest disease association

Genetic Diseases, Inborn

Via encoding gene KRT17 · Genetic evidence · score 0.68

Research activity

Emerging research

1 papers · latest 2019

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Type I keratin involved in the formation and maintenance of various skin appendages, specifically in determining shape and orientation of hair.

View complete UniProt function annotation

Type I keratin involved in the formation and maintenance of various skin appendages, specifically in determining shape and orientation of hair (By similarity). Required for the correct growth of hair follicles, in particular for the persistence of the anagen (growth) state (By similarity). Modulates the function of TNF in the specific context of hair cycling. Regulates protein synthesis and epithelial cell growth through binding to the adapter protein SFN and by stimulating Akt/mTOR pathway (By similarity). Involved in tissue repair. May be a marker of basal cell differentiation in complex epithelia and therefore indicative of a certain type of epithelial 'stem cells'. Acts as a promoter of epithelial proliferation by acting a regulator of immune response in skin: promotes Th1/Th17-dominated immune environment contributing to the development of basaloid skin tumors (By similarity). May act as an autoantigen in the immunopathogenesis of psoriasis, with certain peptide regions being a major target for autoreactive T-cells and hence causing their proliferation

Subcellular location

Cytoplasm
Domains and Gene Ontology detail (14)

Domains & features

IF rod

Gene Ontology

  • Ccornified envelope
  • Ccytoskeleton
  • Ccytosol
  • Cintermediate filament cytoskeleton
  • Ckeratin filament
  • Fstructural constituent of skin epidermis
  • Pepithelial cell differentiation
  • Phair follicle morphogenesis
  • Pintermediate filament organization
  • Pmorphogenesis of an epithelium
  • Ppositive regulation of cell growth
  • Ppositive regulation of hair follicle development

432 aa · 48 kDa

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene KRT17

Gene-level evidence surfaced through the gene KRT17 that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Genetic Diseases, Inborn
0.68Moderately supported

Genetic evidence dominant · Open Targets 0.41

Ovarian dysfunction
0.39Limited support

Genetic evidence dominant · Open Targets 0.23

Temporomandibular Joint Disorders
0.28Limited support

Genetic evidence dominant · Open Targets 0.17

Psoriasis
0.27Preliminary

Animal model evidence dominant · Open Targets 0.12 · no direct causal or clinical evidence

View evidence synthesis (4)
Genetic Diseases, InbornModerately supported
0.68
agreement 0.540.82
Genetic100%Literature1%

Open Targets aggregate 0.41 · 2 independent evidence families

Ovarian dysfunctionLimited support
0.39
agreement 0.270.51
Genetic100%

Open Targets aggregate 0.23 · 1 independent evidence family

Temporomandibular Joint DisordersLimited support
0.28
agreement 0.170.41
Genetic100%

Open Targets aggregate 0.17 · 1 independent evidence family

PsoriasisPreliminary
0.27
agreement 0.130.42
Animal model47%Literature45%RNA expression8%

Open Targets aggregate 0.12 · 3 independent evidence families · no direct causal or clinical evidence

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Genetic Diseases, Inborn0.41
Ovarian dysfunction0.23
Temporomandibular Joint Disorders0.17
Psoriasis0.12

Tractability

AntibodiesEmerging

Feasibility evidence (go cc med conf) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (uniprot ubiquitination and database ubiquitination) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (3)
AB · GO CC med confPR · UniProt UbiquitinationPR · Database Ubiquitination

Raw Open Targets tractability assessment buckets, by modality.

Research activity

1 papers · to 2019

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Recent

Europe PMC papers linked directly to this protein.